Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
TG Therapeutics Inc (NASDAQ: TGTX) closed the day trading at $37.37 down -2.48% from the previous closing price of $38.32. In other words, the price has decreased by -$2.48 from its previous closing price. On the day, 2.76 million shares were traded.
Ratios:
For a better understanding of TGTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.04 and its Current Ratio is at 4.02. In the meantime, Its Debt-to-Equity ratio is 1.07 whereas as Long-Term Debt/Eq ratio is at 1.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on October 29, 2024, initiated with a Buy rating and assigned the stock a target price of $50.
On August 02, 2023, Goldman Upgraded its rating to Neutral which previously was Sell and also lowered its target price recommendation from $16 to $12.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 03 ’25 when Power Sean A sold 11,337 shares for $30.29 per share. The transaction valued at 343,443 led to the insider holds 670,632 shares of the business.
Power Sean A sold 10,021 shares of TGTX for $285,939 on Jan 06 ’25. The CFO now owns 660,611 shares after completing the transaction at $28.53 per share. On Jan 06 ’25, another insider, Power Sean A, who serves as the Officer of the company, bought 10,021 shares for $28.53 each.
Valuation Measures:
As of this moment, TG’s Price-to-Earnings (P/E) ratio for their current fiscal year is 153.16, and their Forward P/E ratio for the next fiscal year is 21.33. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.00. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.35 while its Price-to-Book (P/B) ratio in mrq is 24.91.
Stock Price History:
Over the past 52 weeks, TGTX has reached a high of $46.48, while it has fallen to a 52-week low of $16.21. The 50-Day Moving Average of the stock is -0.13%, while the 200-Day Moving Average is calculated to be 17.65%.
Shares Statistics:
A total of 158.17M shares are outstanding, with a floating share count of 142.95M. Insiders hold about 9.96% of the company’s shares, while institutions hold 62.70% stake in the company.
Earnings Estimates
TG Therapeutics Inc (TGTX) is presently subject to a detailed evaluation by 5.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.27, with high estimates of $0.4 and low estimates of $0.15.
Analysts are recommending an EPS of between $1.33 and $0.58 for the fiscal current year, implying an average EPS of $0.95. EPS for the following year is $1.8, with 5.0 analysts recommending between $2.52 and $1.04.
Revenue Estimates
6 analysts predict $147.76M in revenue for the current quarter. It ranges from a high estimate of $192.05M to a low estimate of $136.4M. As of the current estimate, TG Therapeutics Inc’s year-ago sales were $73.47MFor the next quarter, 6 analysts are estimating revenue of $153.05M. There is a high estimate of $162M for the next quarter, whereas the lowest estimate is $148M.
A total of 6 analysts have provided revenue estimates for TGTX’s current fiscal year. The highest revenue estimate was $633.4M, while the lowest revenue estimate was $574.51M, resulting in an average revenue estimate of $596.09M. In the same quarter a year ago, actual revenue was $329MBased on 6 analysts’ estimates, the company’s revenue will be $824.6M in the next fiscal year. The high estimate is $893.8M and the low estimate is $692.6M.
